Developer of amino acids designed to make valuable products in a sustainable way. The company has invented a novel enzymatic method for synthesizing noncanonical amino acids (NCAA) also called unusual or unnatural amino acids and the proprietary approach enables over 100 NCAA to be synthesized with perfect enantiopurity in just a single step, enabling clients…

plasmid sequencing services

Developer of protein therapeutics intended for neuro-inflammation and oncology. The company leverages breakthroughs in synthetic biology and deep learning to develop proprietary non-antibody scaffold proteins that bind to disordered regions of target proteins in a sequence-specific manner, providing clients with therapeutics to effectively target disordered proteins.

Manufactures laboratory glassware and glass tools for scientific and industrial uses of all sorts.

Developer of therapeutic drugs.

Operator of a pharmaceutical company aimed at spearheading personalized mitochondrial medicines for patients with complex diseases, such as Alzheimer’s dementia, heart failure, and cancer. The company’s approach merges mitochondria biology with pharmaceutical drug development by drugging the proteases of the mitochondrial inner membrane, thereby providing healthcare professionals with medicines for patients with complex diseases.

in stealth mode

Radar Therapeutics leverages the explosion in single-cell transcriptomic data, advances in our understanding of RNA-editing enzymes, and simple, elegant logic gates to make “smart” mRNAs.

late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and will not require light-enhancing goggles)

Keylika is developing the world’s first Rx buccal patch to treat iron deficiency anemia, combining the ease of oral supplements with injectable efficiency—without the drawbacks.